Antisense oligonucleotides against human protein kinase C

Details Antisense oligonucleotides against human protein kinase C Antisense oligonucleotides against human protein kinase C

1995-06-07

1999-03-23

LeGuyader, John L.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

435 6, 435 911, 435325, 435354, 435366, 435368, 435371, 435375, 536 231, 536 2431, 536 245, A61K 4800, C07H 2104, C12Q 168, C12N 1585

Patent

active

058859705

ABSTRACT:
Compositions and methods are provided for the treatment and diagnosis of diseases associated with protein kinase C. Oligonucleotides are provided which are targeted to nucleic acids encoding PKC. Oligonucleotides specifically hybridizable with a translation initiation site, 5'-untranslated region or 3'-untranslated region are provided. Oligonucleotides specifically hybridizable with a particular PKC isozyme or set of isozymes are also provided. Methods of treating animals suffering from disease amenable to therapeutic intervention by modulating protein kinase C expression with an oligonucleotide targeted to PKC are disclosed.

REFERENCES:
patent: 4511713 (1985-04-01), Miler et al.
patent: 4757055 (1988-07-01), Miller et al.
patent: 4806463 (1989-02-01), Goodchild et al.
patent: 5004810 (1991-04-01), Draper
patent: 5034506 (1991-07-01), Summerton et al.
patent: 5087617 (1992-02-01), Smith
patent: 5098890 (1992-03-01), Gerwitz et al.
patent: 5135917 (1992-08-01), Burch
patent: 5138045 (1992-08-01), Cook et al.
patent: 5166195 (1992-11-01), Ecker
patent: 5194428 (1993-03-01), Agrawal et al.
patent: 5264423 (1993-11-01), Cohen et al.
patent: 5264618 (1993-11-01), Felgner et al.
patent: 5276019 (1994-01-01), Cohen et al.
patent: 5286717 (1994-02-01), Cohen et al.
Ono et al. 1988 J. Biol. Chem. 263(14): 6927-6932.
Kawasaki et al. (Jan. 1991), "Synthesis and Biophysical Studies of 2'-dRIBO-2'-F Modified Oligonucleotides" (Conference on Nucleic Acid Therapeutics, Clearwater, FL).
Orkin et al. 7 Dec. 1995 "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy".
Gura, T. 1995 Science 270: 575-577.
Infectious Disease Weekly (23 Oct. 1995), Charles W. Henderson (Publ.).
Boyce et al. 1996 Neurosci. Res. Commun. 18(3): 195-201.
Dean et al. (Mar.) 1995 Proc. Annu. Meet. Assoc. Cancer Res. 36: 413, Abstract 2460.
PR Newswire, 1 Aug. 1996 p. 0801LATH014, (PR Newswire Assoc., Inc.).
Stryer, L. 1975 in: Biochemistry, W.H. Freeman and Company, San Francisco, CA p. 632.
Uhlmann et al. 1990 Chemical Reviews 90(4): 543-584.
Ahmad et al., "Antisense Expression of Protein Kinase C.alpha. Inhibits the Growth and Tumorigenicity of Human Glioblastoma Cells", Neurosurg., 35:904-908 (1994).
Bacher, N. et al., "Isolation and Characterization of PKC-L, A New Member of the Protein Kinase C-Related Gene Family Specifically Expressed in Lung, Skin, and Heart", Mol. Cell. Biol. 11:126-133 (1991).
Ballester, R. and Rosen, O., "Fate of Immunoprecipitable Protein Kinase C in GH.sub.3 Cells Treated with Phorbol 12-Myristate 13-Acetate", J. Biol. Chem., 260, 260(28) :15194-15199 (1985).
Baxter, et al., "PKC-episilon is involved in granuloycte-macrophage colong-stimulating factor signal transduction: Evidence from microphysiometry and antisense oligonucleotide experiments", Biochemistry, 31: 10950-10954 (1992).
Berkowitz, P.T. et al., "Synthesis of 1,2-Dihydro-1-(2deoxy-.beta.-D-Erythro-pentafuranosyl)-2-Oxopyrazine 4-oxide, a potent analog of deoxyuridine", J. Med. Chem., 16: 183-184 (1985).
Borek, C. et al., "Long-chain (sphingoid) bases inhibit multistage carcinogenesis in mouse C3H/10T1/2 cells treated with radiation and phorbol 12-myristate 13-acetate", Proc. Natl. Acad. Sci., 88, 1953-1957 (1991).
Brandt, et al., "District Patters of Expression of Different Protein Kinase CmRNA's in Rat Tissues", Cell., 49:57-63 (1987).
Coussens et al., "Multiple, Distinct Form of Bovine and Human Protein Kinase C Suggest Diversity in Cellular Signaling Pathways", Science, 233:859-866 (1986).
Endo, et al., "Cell Membrane Signaling as Target in Cancer Therapy: Inhibitory Effect of N,N-Dimethyl and N,N,N,-Trimethyl Sphingosine Derivatives on In Vitro and In Vivo Growth of Human Tumor Cells in Nude Mice", Cancer Research, 51:1613-1618 (1991).
Farese, et al., "Antisense DNS downregulates protein kinase C isozymes (beta and alpha) and insulin-stimulated 2-deoxyglucose uptake in rat adipocytes", Antisense Res. Dev., 1 (1): 35-42 (1991).
Finkenzeller, G., "Sequence of Human Protein Kinase C .alpha.", Nucleic Acids Research, 18:2183 (1990).
Gescher, A. and Dale, I.L., "Protein Kinase C-A Novel Target for Rational Anti-Cancer Drug Design", Anti-Cancer Drug Design ,4:93-105 (1989).
Godson, et al., "Inhibition of Expression of Protein Kinase C .alpha. by Antisense cDNA Inhibits Phorbol Ester-Mediated Archidonate Release", The Journal of Biological Chemistry, 268:11946-11950 (1993).
Hackh's Chemical Dictionary, Grant, et al. (ed.), McGraw-Hill Book Company, New York, p. 312.
Hegemann, L. and G. Mahrle, Pharmacology of the Skin, H. Mukhtar, ed., pp. 357-368, CRC press, Boca Raton, FL, 1992.
Hidaka, H. and Hagiwara, M., "Pharmacology of the isoquinoline sulfonamide protein kinase C inhibitors", TIPS, 8:162-164 (1987).
Maister, Bioworld Today, Apr. 29, 1994, p. 3.
Kubo, K., et al., "Primary structures of human protein kinase CBI and BII differ only in their C-terminal sequences", Febs Letters, 223(1): 138-142 (1987).
Krug, E. et al., "Evidence for increased synthesis as well as increased degradation of protein kinase C after treatment of human ostersarcoma cells with phorbol ester", J. of Biological Chemistry, 262(24) : 11852-11856 (1987).
Standaert, et al.,1991, J. Cellular Biochem. (Keystone Symposia on Molecular and Cellular Biology, 18-25 Jan.), Suppl. 15B, p.26, abstract CA 211.
Maier, et al., "An oligomer targeted against protein kinase C alpha prevents interleukin-1 alpha induction of cycloxygenase expression in human endothelial cells", Exp. Cell. Res., 205 (1) : 52-58 (1993).
Marcus-Sekura, "Techniques for Using Antisense Oligodeoxyribonucleotides to Study Gene Expression", Analytical Biochemistry, vol. 172, issued 1988, 289-295.
Nielsen, P.E., et al., "Sequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide", Science, 254: 1497-1500 (1991).
Nishizuka, Y., "The Molecular Heterogeneity of Protein Kinase C and its Implications for Cellular Regulation", Nature, 334: 661-665 (1988).
Osada, S. et al., "A phorbol ester receptor/protein kinase, PKC.eta., a new member of the protein kinase C family predominantly expressed in lung and skin", J. of Biological Chemistry, 265(36) : 22434-22440 (1990).
Parker et al., "The complete primary structure of protein kinase c-the major phorbol ester receptor", Science, 233:853-866 (1986).
Rothenberg, et al., "Oligodeoxynucleotides as Anti-Sense Inhibitors of Gene Expression: Therapeutic Implications", J. Natl. Cancer Inst., 81(20) :1539-1544.
Sakanou, Youichirou et al., "Protein Kinase C Activity as Marker for Colorectal Cancer" Int. J. Cancer 48: 803-806 (1991).
Sambrook et al., Molecular Cloning. A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1989, vol. 2, P. 10.59.
Simons et al., "Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo", Nature 359:67-70 (1992).
1993 Catalog of Products for DNA Research, Glen Research, Sterling, VA, p. 21.
Watson, et al., 1987, in Molecular Biology of The Gene, fourth edition, Benjamin/Cummings Publishing Company, Menlo Park, CA p. 241.
Webster's II New Riverside University Dictionary, Soukkhanov, et al., (eds.) 1984, Houghton Mifflin Company, Boston, MA p. 68.
Weinstein, I.B., "Cancer Prevention: Recent Progress and Future Opportunities", Cancer Research, 51:5080s-5085s (1991).
Young, S. et al., "Down-regulation of protein kinase C is due to an increased rate of degradation", Biochem., 244:775-779 (1987).
Zon, "Oligonucleotide Analogues as Potential Chemotherapeutic Agents", Pharmaceuticals Res., 5:539-549 (1988).

Affiliated with

Also associated with

Rating

Antisense oligonucleotides against human protein kinase C does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antisense oligonucleotides against human protein kinase C, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense oligonucleotides against human protein kinase C will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2125522